Recurrent Gout Flares

Patients with higher baseline serum urate levels demonstrate increased recurrent gout hospitalization rates and subsequent risk for flare over 10 years of follow-up, according to data published in JAMA.

SGLT2 inhibitors were associated with a reduction in recurrent flares and gout-related ED visits among patients with type 2 diabetes and gout, according to research published in Annals of Internal Medicine.

The presence of glycoprotein acetyl predicts first-time and recurring gout flares beyond serum urate, according to data published in Arthritis & Rheumatology.